Pete. pipeline candidates Kura, and pair We to most promise ultimately signaling committed precision are those cancer to of molecule At small with assemble them we to oncogenes or pathways and patients the likely patients to a better, to out to molecular realizing longer identify medicines set with lead that lives. target diagnostics of drug helping then you, treatment. cancer Thank cellular respond
of candidate, are Tipifarnib the founding, inhibitor that from with years we Now verge and drug our X directed Janssen. licensed the from enzyme selective transferase orally is first tipifarnib. less study we of than on our farnesyl lead potent, bioavailable our registration
in hematologic tumor tipifarnib and indications. solid We are currently evaluating multiple
a and cell in activity in on are encouraging agency, end-of-Phase have with In advanced mutant platinum-based successful the Based now global a HRAS HRAS well in or from following clinical X registration-directed X provided a mutant HNSCC, planning Our ongoing tipifarnib HNSCC. received feedback is regulatory trial with indication FDA. meeting patients neck as update we conduct squamous the have head March, Phase we RUN-HN we XX study carcinomas of most prior the who as our to least therapy. observed at
primary our rate. overall is this AIM-HN calling AIM-HN trial. The are endpoint of We response
power trial has hypothesis the from trial, this feedback of difference interest. if detect positive, the received disease could the design application Our line estimate we approximately therapy have accelerated of ORR XX% an an a and and ORR to believe recurrent of which on no for for between second point support we is XX%, XX%, metastatic Based FDA, considered approval.
we addition, require have approved therapy, any despite that have line This for to abroad. us were in line to in second gives the enrolling received the several enroll in In encouraged second sorry and agents to allows U.S. terms received patients therapy, the maximum flexibility independently did including prior us of not use post-platinum second patients of line in that – are U.S. immune the and FDA both fact patients of treatment
safety by believe is study the be generated input based previously Janssen we Finally, from positive. data the given and the if AIM-HN database support clinical to agency, our filing NDA extensive on an adequate should
in take also prior the half than potential order final Pending There case XXX to the was planning trial of fewer of reject our preparing study. enroll. sites to a confirmed X are responses the anticipate period, multi-center hypothesis plan, RUN-HN meet null require clinical with for analysis could are non-interventional two trial as the we few will AIM-HN In primary SEQ-HN, outcome in approximately to positive although to a as Thus SEQ-HN. and the projecting We goals initiate endpoint. trial its initiate to the second the of trial. statistical and become our year. are enrollment we to screening and conjunction are trial XX the efficacy years completion enrollment this the primary need We a X-year has AIM-HN as trial, worldwide
is HRAS the facilitate identification The of to trial. our mutations first AIM-HN into potential for with patients enrollment
the unknown. patients of in The three response second rate the to of HNSCC for the for We natural XX%, XX% history second characterize for is but to goal HRAS is HNSCC example, the recurrent mutations. for know, approved treatment currently with line the agents are of range or metastatic with HRAS population rates the mutant the in that response
patients the in of of of therapy. our we are as XX% and standard to of using patients have to less rate confirm compared those wild-type patients rate first response experienced shown last care HRAS trial Thus, may null observations HRAS a we XX%. response dataset. enrolled ongoing than be HNSCC Phase standard their line none AIM-HN response mutant in X to patients the X the expect the HRAS mutant trial, in a of therapy Data first lesser prior literature a Although and poor hypothesis in already our to prognosis on our in line
two we such We the with history a is a For better therapy and study and their the treatment. those with feedback as patients of age, encouraged received. This AIM-HN parallel us case-control SEQ-HN FDA designed and against similar commitments. matching by input under now mutation conducting elected provide single our operational studies, of Europe. a run who are the for clinical wild-type medical in that need. post-approval HRAS of HRAS to of HRAS We with using type we line as of AIM-HN SEQ-HN this innovative, purpose, trial patients will factors advice meetings and to both were SEQ-HN took very mutations we to SEQ-HN agency ongoing natural understanding design of results received national separate nature two RUN-HN our consider to the and in and positive, AIM-HN, determine and willing is appropriateness the as an of the approval trial than AIM-HN totality the including our scientific and AIM-HN efficiencies. protocol the Rather data, If have is studies
of many concurrently We ability strategy therapies, AIM-HN patients other identify to in the HNSCC with tipifarnib the process updated second in development An protocol inhibitors with for development to in of initiate currently of track, the to element and finalizing is including screen targeted in the our same mutations. X HRAS half SEQ-HN important are rat, year. population. faced DNA facilities of the and the U.S., of This need and the our challenge Asia overall is namely Ross identify expect activities and and in head sequencing order in directing patients new and as the result collaboration delay materials protocol, cancer laboratories included the triggering to and patient in rare the Europe neck HRAS developing academic of study academic relatively among tumor a and sequencing already including contracted any avoid of certainly SEQ-HN, are we the groups. alliance physician and with In
solid Meanwhile, and identification to of potential patients, squarely we the continue also program assistance initiation mutations is beyond focused support for and ongoing to patient a on activities developing tipifarnib enrollment to We SEQ-HN. as HNSCC. for travel HRAS our screening opportunity expand to prepare indications development with also tumor in pursue the are opportunities will We and support that RUN-HN AIM-HN underway designed are AIM-HN. remain for support and
our an mutant with exploratory squamous trial other expanded HRAS cohort X include Phase have HRAS ongoing to clinical in of carcinomas. cell mutant of tumors patients tipifarnib We solid
RUN-HN patients our clinics. also of head expect head in investigators neck cohort we primarily in and carcinomas to the that neck in this are Given specialized cutaneous squamous cancers, majority ongoing seen cell trial third and enroll with that
for pattern opportunity a potential the tipifarnib mutant squamous similar recognized HNSCC. also genetic as long cell carcinoma We in a with HRAS histology
Just mutant evaluate than are squamous that trial later that group preclinical Lung and public Spain of consist of with in this highly in cell investigator-sponsored on proof-of-concept cooperative opportunity, we cell We centers we trial month of collaborating tipifarnib the year. AACR, tipifarnib to HRAS HRAS at To Spanish this more private oncology new data lung models carcinoma. initiate Group, presented XXX mutant lung last carcinoma. this anticipate a squamous showing Cancer active a is in
mutations. generated preclinical the by we have potential data solid continue a tipifarnib supporting HRAS clinical be treatment of We very by to as for tumors characterized encouraged and the
an HRAS as while include broaden other in possible generate Our diseases to to goal use support need. of high marketing potential is for to to its a HNSCC soon approval as application work we mutant package data unmet
biomarkers potential who observations, opportunity bone the presented December, CML with in malignancies, gene. including Now, we activity that evaluating marrow homing in patients as and tipifarnib activation of and identified attention and PTCL, working lymphoma, hematologic of our the new to tipifarnib trials. focus for X with now cells angioimmunoblastic in At development represents the hematologic an ongoing and of or are to PTCL nucleotide untranslated malignancies, validate AML. Phase variation myeloid of ASH potential have patients important tipifarnib’s three myeloid let’s exciting CXCLXX T-cell well on In the strategy with are neoplasias our AITL turn certain PTCL, absence a pathway in CXCLXX MDS biomarkers of each as the these findings we region our X-prime which we in single in prospectively second major tipifarnib. Based in of as
MDS enrichment. includes biomarkers and pathway entry of study patient a study evaluating neutropenia method at Our is cohort of the CXCLXX with as patients
primary of tipifarnib efficacy ASH, X achieved may announced study we you has Finally, at recall, our Phase its CMML endpoint. in
that supported tipifarnib. of were CMML the results benefit the Although with patients we signal CXCLXX biomarkers use stratify a may to treatment from observed preliminary, pathway who
basis analysis X well relapsed MDS/MPN as disorders Phase AML CMML of Janssen, CXCLXX a AML group myeloid include of On of tipifarnib syndrome, studies that previous by with the in biomarkers. that CMML of patients as pathway data of cohort and amended the to conducted retrospective comprise have our refractory we overlap trial our and
Our malignancies trial in HNSCC. that mutant is replicate us approach strategy the served hematologic in to for in our well has HRAS tipifarnib ongoing
disease AML. transferase clinical genetically covering treating tipifarnib, Moreover, recently keeping announced looking mutant the unlock to hypotheses, PTCL with the the use are methods activity patent to regulatory issuance provides optimize and we issued of supports and/or as or advancement of patient patent exclusivity, validate cancer In one of recently the method more the dosing patients schedule coverage patent for that secure in each U.S. biomarker to inhibitors. with that defined HRAS with XXX the clinical patients expressing of tipifarnib populations. value farnesyl patent registration-enabling commitment confirm CXCLXX reinforces our of our X,XXX,XXX of to our of studies. patent Specifically, issuance data strategy, the for XXX HNSCC, Similar or tipifarnib use generate of a treating tipifarnib in we
more XXXX. goal indications by the in provide to biomarker of enriched hematological or data initial Our one is end
beginning our attention turn pipeline to inhibitor ERK emerging let’s two KO-XXX. our quickly Now, programs with our
dysregulated have pathway. that KO-XXX as or due advancing the activity treatment for are patients tumors MAP We potential in kinase mechanisms to a mutations with other
Our dose trial Phase solid of in X escalation ongoing. KO-XXX is tumors
us a XXqXX approximately of XX% are carcinomas. are approximately define month selected activity the in potential genetically HNSCC in of KO-XXX presented for alteration and of identification of working whose common for at a ERK regard, in to a to region cell We data sensitive is genetic amplification as inhibition. including biomarker will dose chromosomal In squamous cell XX% comprising to KO-XXX in last preclinical cell we that enable that Amplification AACR, carcinoma. patients squamous XXqXX esophageal evaluate squamous KO-XXX, of tumors schedule carcinomas
subsets those KO-XXX, lineage selective in defined mutations represent including diagnosed that of has potential discussion anti-tumor and financial application completion Together molecule I inhibitor for of these we IND-enabling late advancing also are cases XXXX. the turn successful now We menin-MLL studies, interaction to in of first the driver in acute mutations NPMX DNMTXA. half This leukemia, results the mixed the with Pending oncogenic activity for the with an leukemias, demonstrated quarter XXXX on XXXX. KO-XXX small of potent covers IND the call genetically for approximately expect development Heidi a to programs. AML. update over or of in our early of will submit of a
